Lipids & metabolic liver disease
Risk of metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis: a large-scale study from the Middle East
Authors' conclusion
Reliance solely on metabolic risk-based case finding may miss individuals at risk of advanced fibrosis, highlighting the value of broader fibrosis risk assessment strategies.
Study context
- Population
- Adults attending Dubai Academic Health Corporation, January 2018–August 2023
- Outcome
- Prevalence of MASLD risk factors (T2D; obesity with ≥1 cardiometabolic risk factor; and/or raised ALT) and moderate-high risk of advanced fibrosis by FIB-4 (≥1.3 for <65 years; ≥2.0 for ≥65 years)
Methodological detailsmulticenter, real-world cohort
- Multicenter
- Real-world cohort
Main finding
As reported in the abstract
At risk of MASLD; moderate-high risk of advanced fibrosis
Screened at risk of MASLD
n = 46,412, 49.0%
Moderate-high risk of advanced fibrosis among those at risk of MASLD
21.7%
Moderate-high risk of fibrosis among those without MASLD risk factors, including those without obesity
15.0%
Observational data: associations, not effects.
Original publication
Risk of metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis: a large-scale study from the Middle East. Int J Obes (Lond). Published 30 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →